Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

18

Revenue 2017

Takeda

The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Takeda's 2013 sales performance.

Takeda

Shire’s angioedema drug Takhzyro recommended in Europe

Shire’s angioedema drug Takhzyro recommended in Europe

Approved in the US in August, the drug is important for Shire, which is in the midst of a $62bn acquisition by Takeda. ... The news will help bolster Takeda CEO Christophe Weber’s argument that the deal makes sense.

AZ nabs US approval for new leukaemia drug Lumoxiti

AZ nabs US approval for new leukaemia drug Lumoxiti Seattle Genetics/Takeda’ s classical Hodgkin lymphoma therapy Adcetris (brentuximab vedotin) and Roche’s Kadcyla (trastuzumab emtansine) for breast cancer.

Takeda rebels take aim at Shire acquisition

Takeda rebels take aim at Shire acquisition Takeda rebels take aim at Shire acquisition. Opposition to Takeda’s yet-to-be-finalised $63bn takeover of Shire appears to be building among some shareholders in Japan. ... A small but increasingly vocal group of rebel investors – including members

Darzalex powers ahead with frontline myeloma approval in Europe

Darzalex powers ahead with frontline myeloma approval in Europe Its pharma division Janssen has gained EU approval for its use alongside Takeda’s Velcade (bortezomib), melphalan and prednisone (VMP) for newly-diagnosed myeloma patients who are ineligible for high-dose

Result pages: 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 ()

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Bedrock Healthcare Communications

Bedrock Healthcare Communications is a privately owned, award winning communications agency that creates and delivers highly effective, insight driven medical...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe's leading hub for life sciences innovation...

Infographics